Bisindolylmaleimide IX
A protein kinase inhibitor.
General information
Bisindolylmaleimide IX is a protein kinase C inhibitor derived from maleimide (ChEBI). It was shown to be active also against various other protein kinases and targeting a spectrum of biological processes (Gupta et al., 2021 and references therein). It was also observed to be active against SARS-CoV-2 and its 3C-like protease in vitro (Gupta et al., 2021).
Bisindolylmaleimide IX on PubChem
Synonyms
Ro 31-8220; BIM IX
CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
3CLpro Enzyme assay In vitro In silico |
in silico; in vitro enzyme assay; Vero E6 cells | 3.81 | The compound was predicted to bind the SARS-CoV-2 3C-like protease by computational methods. It inhibited viral entry with IC50 of 28.18 µM and viral spread with IC50 of 381.5 µM in Vero E6 cells. In an enzymatic assay it inhibited the 3C-like protease with IC50 of ca. 113.7 µM. |
Jan/14/2021 |
